TD Cowen raised the firm’s price target on Hims & Hers to $44 from $28 and keeps a Buy rating on the shares. The firm continues to believe ...

One popular option, Weight Loss by Hers, is a holistic program personalized for you. The program features four pillars of ...

Eli Lilly & Co. said Tuesday it's cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will also ...

Five days before the Academy Awards, nearly every nominee gathered for a cocktail reception, dinner and class picture shoot ...

We recently published a list of Jim Cramer on 10 Stocks With The Biggest Declines Last Week. In this article, we are going to ...

Hims & Hers on Monday released fourth-quarter results that disappointed on gross margin and sparked concerns about the future ...

Hims & Hers (HIMS) made a killing last year selling an off-brand version of Ozempic, but with the drug’s shortage now over, ...

Hims & Hers is stopping its sales of an alternative to blockbuster weight-loss drugs Wegovy and Ozempic. That follows the U.S ...

Hims & Hers stock tumbled after the company confirmed it would stop selling some compounded weight-loss drugs.

It is bad news for telehealth company Hims & Hers Health (HIMS) today as shares plummeted after its earnings report from yesterday and some ...

Telehealth provider Hims & Hers said it will tell consumers they need to seek “alternative options on the commercial dosing,” ...

Hims & Hers will stop selling generic semaglutide after the FDA said the shortage of GLP-1 medications is resolved.